ALPHARETTA, Ga.–(BUSINESS WIRE)–January 8, 2016–

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission related to Clearside’s proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not been determined. Clearside plans to list its common stock on the NASDAQ Global Market under the ticker symbol “CLSD.”

RBC Capital Markets and Stifel will serve as joint book-running managers for the proposed offering. Needham & Company and Wedbush PacGrow Healthcare will serve as co-managers.

This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, can be obtained from RBC Capital Markets, LLC, Brookfield Place at 200 Vesey Street, 8th Floor, New York, New York 10281-8098; Attention: Equity Syndicate; Phone: (877) 822-4089, Email: equityprospectus@rbccm.com, or from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104 or by telephone at (415) 364-2720. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space (SCS™) microinjector to reach diseased tissue through the SCS™. Clearside holds intellectual property protecting the delivery of drugs of any type through the SCS™ to reach the back of the eye.

Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
Chief Financial Officer
charlie.deignan@clearsidebio.com
or
The Trout Group
Investors:
Matthew Beck, 646-378-2933
mbeck@troutgroup.com